First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow-to-Debt Ratio
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued cash flow-to-debt ratio. First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a Cash Flow-to-Debt Ratio of -0.98x as of March 2026, meaning its operating cash flow of $-32.56 Million could theoretically repay -1% of its total liabilities ($33.11 Million) in one year. See First Tracks Biotherapeutics, Inc. Ordin free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Cash flow-to-debt ratio of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. Historical debt coverage capacity for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued across 2 annual periods. Also explore TRAXV shareholders equity momentum to track the company's year-over-year net asset growth rate.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow-to-Debt Ratio by Year (2023–2024)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued cash flow-to-debt ratio by year from 2023 to 2024. Year-by-year debt coverage analysis for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued. For the full cash flow conversion analysis, see cash efficiency ratio of First Tracks Biotherapeutics, Inc. Ordin.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.50x | $-125.81 Million | $50.30 Million | ▲ +7.9% |
| 2023 | -2.71x | $-93.00 Million | $34.26 Million | — |